The Current State and Facts of CRISPR Technology
The origins of CRISPR technology, the Casgevy treatment, clinical successes, costs, and the current status in cancer treatment are examined with scientific data.
CRISPR technology has evolved from a bacterial defense system into programmable genetic scissors, transforming into a major treatment method for severe blood disorders.
The Birth of CRISPR Technology
The repeated sequences noticed by Japanese researchers in bacterial DNA in 1987 were defined years later as genetic memory. This billion-year-old defense system was transformed into programmable genetic scissors in 2012 and named CRISPR. Emmanuelle Charpentier and Jennifer Doudna were awarded the 2020 Nobel Prize in Chemistry for this groundbreaking work.
Casgevy Treatment and Approval Process
Approved in the US in 2023, Casgevy became the first CRISPR/Cas9 product for sickle cell disease and beta-thalassemia. As of 2026, the treatment age has been lowered to two, eliminating long-term pain crises and the need for blood transfusions in a large portion of patients. These results are of historical significance for sickle cell and beta-thalassemia patients.
Application Method and Cost
Instead of directly repairing the defective gene, Casgevy reactivates fetal hemoglobin production in the patient's stem cells. Requiring high-dose chemotherapy to prepare the bone marrow, this personalized stem cell treatment has a US list price of around $2.2 million. Although the age limit has been expanded, clinical data are predominantly derived from the five to eleven age group.
In Vivo Application Trials
Aiming to make edits inside the body without extracting cells, an experimental treatment called lonvo-z passed a significant threshold in the Phase 3 stage. Developed for hereditary angioedema, this single infusion significantly reduced attacks while enabling the majority of patients to discontinue preventive treatment. However, this treatment has not yet received official approval.
Status in Cancer Treatment
Although cancer is a genetic disease, there are currently no FDA-approved CRISPR cancer treatments. The continuous evolution of cancer cells and the complexity of the tumor ecosystem make the safe and effective delivery of genetic regulators challenging. Research continues to strengthen immune cells.
Ethical Boundaries and Future Expectations
The unethical editing of human embryos in 2018 caused a major uproar worldwide, highlighting the importance of scientific boundaries. CRISPR should not be regarded as either a complete miracle or a total disappointment; successes and limitations are progressing together.